The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma

Orthotopic and ectopic hepatocellular carcinoma models were constructed by implanting Hepa1-6 cells at different body sites of mice. Immune agents were administrated via three ways, including intratumoral injection into one site of the tumor, intraperitoneal injection, and subcutaneous injection.